SEVER
Tropospheric scatter, also known as troposcatter, is a method of communicating with microwave radio signals over considerable distances – often up to 500 kilometres (310 mi) and further depending on frequency of operation, equipment type, terrain, and climate factors. This method of propagation uses the tropospheric scatter phenomenon, where radio waves at UHF and SHF frequencies are randomly scattered as they pass through the upper layers of the troposphere. Radio signals are transmitted in a narrow beam aimed just above the horizon in the direction of the receiver station. As the signals pass through the troposphere, some of the energy is scattered back toward the Earth, allowing the receiver station to pick up the signal.
Beyond's analysis on SEVER
Recent news mentioning SEVER
- — SEVER LIFE SCIENCES B.V. WIRD ÜBER IHRE TOCHTERGESELLSCHAFT NORDIC PHARMA, INC. PATIENTENDATEN UND DIE ERGEBNISSE EINER STUDIE ZUR PATIENTENERFAHRUNG MIT LACRIFILL® CANALICULAR GEL, EINER NEUARTIGEN THERAPIE ZUR KONTROLLE DER AUGENOBERFLÄCHE, IM RAHMEN DER TAGUNG DER AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2026 VORSTELLEN
- — NANO Nuclear Announces Participation in Several Investor Conferences
- — Goliath Reports Several Holes, Up To 9.89 g/t AuEq Over 12.00 Meters From Surebet Zone Confirming Continuity, As Well As 24.97 Meters Of 0.70 g/t AuEq From Newly Identified And Extensive Big Bulk Zone, Golddigger Property, Golden Triangle, B.C.
- — Honda delays next-gen CR-V hybrid production several months in US, Canada
- — Indonesian parliament agrees higher severance benefits in new labour law
- — Heavy rains lead to Senegal floods, government reports several deaths
- — Strikes by North Sea oil workers could ‘severely disrupt’ UK fuel supplies
- — THEON secures new orders of c.€50 million and is pre-selected for several higher-value contracts and options
- — New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
- — AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
- — Roche launches newborn screening test for three severe genetic conditions
- — Sham City: verdict on financial breaches is damning and punishment must be severe | Jonathan Wilson